SPY
761.48
QQQ
697.18
−2.54%
BTC/USD
77,159.39
−0.82%
DIA
522.57
−0.03%
GLD
363.29
−1.43%
TLT
81.87
+0.47%
Try
Free
US
Sign in
Register
My Account
Benzinga
Premium Services
Services
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
Erasca Inc
ERAS
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$14.98
-0.14
-0.93%
Last update: Oct 30, 7:37 AM
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Compare
Options
Stock Report
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
Erasca Financials
Erasca (ERAS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the
Benzinga Newsdesk
Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials
Erasca reported updated Phase 1 ERAS-0015 data, outlined pivotal trial plans and priced an upsized $550 million stock offering.
Vandana Singh
PRO
Erasca Q1 EPS $(0.60) Misses $(0.22) Estimate
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.22) by 172.73 percent. This is a 445.45 percent decrease over losses of $(0.11) per share from the
Benzinga Newsdesk
PRO
Erasca Q4 EPS $(0.10), Inline
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year.
Benzinga Newsdesk
PRO
Erasca Q3 EPS $(0.11), Inline
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Erasca Q2 EPS $(0.12) Misses $(0.11) Estimate
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 58.62 percent increase over losses of $(0.29) per share from the same
Benzinga Newsdesk
